Adverse Outcome Pathway on impaired interleukin-1 receptor type I (IL-1R1) signaling leading to impaired T-cell dependent antibody response

Yutaka Kimura, Setsuya Aiba, Takao Ashikaga, Takumi Ohishi and Kiyoshi Kushima

No 30, OECD Series on Adverse Outcome Pathways from OECD Publishing

Abstract: Stressors that exhibit immunosuppression might act by different mechanisms, i.e. alter the number of cells involved in the immune response, the ability of the cells to produce cytokines, chemokines, antibodies or growth factors, the composition of the subpopulations of cells present at the site of the response, or the function of the cells. This Adverse Outcome Pathway (AOP) describes how impairment of the signaling receptor IL-1R1 in T cells can lead to impaired T cell activation and antibody production, leading to increased susceptibility to infection. The AOP focuses on the blocking of binding of IL-1 to IL-1R1, leading to the Inhibition of Nuclear factor kappa B (NF-kB). This AOP is referred to as AOP 277 in the Collaborative Adverse Outcome Pathway Wiki (AOP-Wiki).

Date: 2023-10-23
References: Add references at CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1787/74834ad1-en (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:oec:envaad:30-en

Access Statistics for this paper

More papers in OECD Series on Adverse Outcome Pathways from OECD Publishing Contact information at EDIRC.
Bibliographic data for series maintained by ().